Ex­clu­sive: Ex-Af­fimed CEO heads to UK nanomed­i­cine biotech; Ja­mi Ru­bin leaves Bound­less Bio af­ter IPO

Adi Hoess de­scribes him­self as some­one who “likes to build” com­pa­nies fo­cused on “chal­leng­ing tech­nolo­gies.” It’s fit­ting, then, that af­ter spend­ing more than a decade …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER